News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

Articles by Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

Decision Factors for SubQ Therapy and Unmet Needs

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

March 5th 2021

Phase 3 FeDeriCa and PHranceSCa Trial Overviews

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

February 26th 2021

Novel Agents for Late-Stage HER2+ MBC

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

February 26th 2021

Practical Advice for Toxicity Management in HER2+ MBC

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

February 19th 2021

Brain Metastases Therapy in Second-Line HER2+ MBC

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

February 19th 2021

Sequencing Therapy in R/R HER2+ MBC

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

February 12th 2021

Newly FDA Approved Therapies: R/R HER2+ MBC

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

February 12th 2021

Moving Metastatic Therapy to Early Stage Setting

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

February 5th 2021

Hormone Therapy in HER2+ Breast Cancer

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

February 5th 2021

De-Escalation of Adjuvant Anti-HER2 Therapy and Chemo

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

January 29th 2021

Adjuvant Systemic Therapy Data Updates

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

January 29th 2021

Adjuvant Systemic Therapy Decision Factors

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

January 20th 2021

HR-/HER2+ Early Stage Breast Cancer: Standards of Care

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

January 20th 2021

Refining Treatment Approaches for HER2+ Breast Cancer

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

January 20th 2021

A discussion on systemic treatment for HER2+ breast cancer and the impact of recent clinical trial data on decision making, including data discussed at the ESMO and SABCS 2020 Annual Meetings.

Perioperative Therapy: ASCO 2020 Data Updates

BySara A. Hurvitz, MD, David Geffen School of Medicine,Aditya Bardia, MD, MPH, FASCO,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center,Sara Tolaney, MD, MPH, Dana-Farber Harvard Cancer Center

August 13th 2020

Metastatic Triple-Negative Breast Cancer Ongoing Trials

BySara A. Hurvitz, MD, David Geffen School of Medicine,Aditya Bardia, MD, MPH, FASCO,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center,Sara Tolaney, MD, MPH, Dana-Farber Harvard Cancer Center

August 13th 2020

ASCO 2020 Data Updates: Metastatic HER2+ Breast Cancer

BySara A. Hurvitz, MD, David Geffen School of Medicine,Aditya Bardia, MD, MPH, FASCO,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center,Sara Tolaney, MD, MPH, Dana-Farber Harvard Cancer Center

August 13th 2020

Metastatic HR+ Breast Cancer Updates

BySara A. Hurvitz, MD, David Geffen School of Medicine,Aditya Bardia, MD, MPH, FASCO,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center,Sara Tolaney, MD, MPH, Dana-Farber Harvard Cancer Center

August 13th 2020

Latest Updated Articles

Refining Treatment Approaches for HER2+ Breast Cancer
Published: January 20th 2021 | Updated:
Hormone Therapy in HER2+ Breast Cancer
Published: February 5th 2021 | Updated:
Decision Factors for SubQ Therapy and Unmet Needs
Published: March 5th 2021 | Updated:
HR-/HER2+ Early Stage Breast Cancer: Standards of Care
Published: January 20th 2021 | Updated:
Newly FDA Approved Therapies: R/R HER2+ MBC
Published: February 12th 2021 | Updated:
Perioperative Therapy: ASCO 2020 Data Updates
Published: August 13th 2020 | Updated:

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Dr Bardia on the Efficacy of Giredestrant in ER+, HER2-Negative Early Breast Cancer